相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
Munehiro Kitada et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Xiaoxuan Li et al.
FRONTIERS IN PHARMACOLOGY (2018)
Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes
Hitoshi Kuwata et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
Seung-Hyun Ko et al.
DIABETES & METABOLISM JOURNAL (2017)
Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
Plamen Kozlovski et al.
DIABETES OBESITY & METABOLISM (2017)
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes
Takehiro Hashikata et al.
HEART AND VESSELS (2016)
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
S. Hong et al.
DIABETES OBESITY & METABOLISM (2016)
DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis
Xiaoling Cai et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2016)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2016 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2016)
The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension
Andrew Bryson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Prevalence of type2 diabetes mellitus among inland residents in China (2000-2014): A meta-analysis
Lili Yang et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
William H. Polonsky et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Complications of Diabetes 2016
Konstantinos Papatheodorou et al.
JOURNAL OF DIABETES RESEARCH (2016)
Teneligliptin in management of type 2 diabetes mellitus
Surendra Kumar Sharma et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
Teneligliptin: expectations for its pleiotropic action
Ryuichi Morishita et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Incretin physiology and pathophysiology from an Asian perspective
Young Min Cho
JOURNAL OF DIABETES INVESTIGATION (2015)
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension
T. Kadowaki et al.
DIABETES OBESITY & METABOLISM (2014)
Prevalence, trends and risk factors for the diabetes epidemic in China: A systematic review and meta-analysis
Hui Zuo et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy
Seiichi Tanaka et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea
Akira Kubota et al.
JOURNAL OF DIABETES INVESTIGATION (2014)
Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
Atef Halabi et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes
Stuart A. Ross
AMERICAN JOURNAL OF MEDICINE (2013)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
T. Kadowaki et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
Miyako Kishimoto
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Cardiovascular risk factors in patients with type 2 diabetes -: Do we follow the guidelines?
FJ del Cañizo-Gómez et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
分享论文
